Coeliac Disease and Immune Health
Immunic Study (Industry Sponsored)
This clinical trial will investigate a potential treatment option for coeliac disease. This could potentially improve quality of life for people with coeliac disease.
Research Objectives
Status
Recruitment
Patient Group
Study location
Study type
Lead investigator
- Dr James Daveson
Clinical trial coordinator
- Emma Brownrigg
Technical title
A three-part double blind, placebo controlled Phase 1 B of IMU-856 in healthy volunteers and patients with coeliac disease
About this research project
This clinical trial will investigate a potential treatment option for coeliac disease. The only effective treatment currently available for coeliac disease is a strict, lifelong, gluten-free diet. With gluten being present in a variety of food and drinks, this study brings hope to people suffering with this disease. This study will assess the safety and tolerability of a potential new oral treatment (IMU-856) when given to people with coeliac disease. This treatment works by blocking a protein found in the gut, which is believed to play an important role in strengthening the delicate lining of the gut in order to prevent damage that might cause an inflammatory reaction. This could potentially improve quality of life for people with coeliac disease.
Our goals:
- Research into faster and more accurate diagnosis
- Improve understanding around the causes of disease and better prediction of disease progression
- Increase survival and quality of life for patients and families
Latest News
![3D Illustration Concept of Human Circulatory System Heart Anatomy](https://www.wesleyresearch.org.au/app/uploads/anatomy-with-lungs-2.jpg)
New Wesley Research Institute Program Offers Hope for Pulmonary Hypertension Patients
![](https://www.wesleyresearch.org.au/app/uploads/GTMTuIYWcAAo6jq.jpg)
QSBC Announces Latest Publications in Spatial Biology
![](https://www.wesleyresearch.org.au/app/uploads/Jillian-Ruhland-e1719878714764.jpg)